Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-meth campaign

This article was originally published in The Tan Sheet

Executive Summary

CHPA is joining Partnership for a Drug-Free America and Missouri, Arizona chapters of the American Academy of Pediatrics in an effort to reduce number of teens abusing methamphetamine. Two-year 1educational campaign will focus on St. Louis, Phoenix metro areas and will involve PSAs, print ads and brochures. PDFA estimates costs of the ads and PR messages will range from $8 mil. to $10 mil., mostly donated pro bono. One PSA will feature actor/musician Henry Rollins exploding the engine of a car to demonstrate meth's effects on the heart, while another will show a guided tour of a filthy meth lab. The pseudoephedrine in OTC cough/cold remedies can be illegally converted into meth...

You may also be interested in...



Tennessee Gets Pseudoephedrine Pharmacy Sale, CHPA Education Program

Tennessee is the sixth state to enact a law restricting pseudoephedrine products to pharmacy sale

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel